New diabetes drug enters final testing phase
NCT ID NCT07394114
Summary
This study is testing whether a new injectable medicine called HDM1005 is better than a placebo (a dummy treatment) at lowering blood sugar in people with type 2 diabetes. It will involve 240 adults whose diabetes is not well controlled by diet and exercise alone. The main goal is to see how much the medicine lowers a key long-term blood sugar marker (HbA1c) over 36 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese PLA General Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.